Stockwinners Market Radar for March 09, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:30 EST Cathie Wood's ARK Investment bought 2.1M shares of Ginkgo Bioworks today

20:28 EST Cathie Wood's ARK Investment bought 354K shares of Coinbase today

19:03 EST Installed Building Products CEO sells $14.3M in common stock - In a regulatory filing, Installed Building Products disclosed that its CEO Jeffrey Edwards sold 125K shares of common stock on March 7th in a total transaction size of $14.3M.

18:31 EST Seagen, Astellas says China's NMPA accepts BLA for enfortumab vedtoin - Astellas Pharma Inc. (ALPMY) and Seagen Inc. (SGEN) announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted the Biologics License Application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. "In China, there were nearly 86,000 new cases of bladder cancer in 2020, and we are working with the NMPA to seek approval for enfortumab vedotin for patients with advanced stage disease," said Ahsan Arozullah, M.D., M.P.H., Senior Vice President and Head of Development Therapeutic Areas, Astellas. "Enfortumab vedotin has become a second- and third-line treatment option for many patients around the world with previously treated locally advanced or metastatic urothelial cancer, and an approval in China may bring this therapy to those patients."

18:20 EST IXHL Stock trading halted, news pending

18:06 EST Stratasys confirms unsolicited acquisition proposal from Nano Dimension - Stratasys (SSYS) confirmed that it has received an unsolicited non-binding indicative offer from Nano Dimension (NNDM) to acquire Stratasys for $18.00 per share in cash. Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, the Stratasys Board of Directors will carefully review and evaluate the proposal to determine the course of action that it believes is in the best interests of the company and Stratasys shareholders.

18:01 EST MediciNova announces additional extension of BARDA contract - MediciNova announced a modification to its contract with the Biomedical Advanced Research and Development Authority, a part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services, to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury. The contract was amended to extend the period of performance until May 31, 2023. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50121C00022.

17:55 EST SVB Financial falls another 21% after Founders Fund tells companies to exit - SVB Financial is down another 21% in post-market trading after Bloomberg reported that Peter Thiel's Founders Fund Peter Thiel, has advised companies to pull money from Silicon Valley Bank amid concerns about its financial stability, according to people familiar with the situation.

17:40 EST Femsa proposes dividend increase of 7.8% for 2023 - Femsa announces that its Board of Directors has proposed an ordinary dividend in the amount of Ps. 12.25B to be paid during 2023. The dividend is subject to approval of the annual shareholders meeting to be held on March 31. This proposal represents an increase of 7.8% compared to the dividend paid during 2022.

17:31 EST Procept BioRobotics CFO sells $1.03M in common stock - In a regulatory filing, Procept BioRobotics disclosed that its CFO Kevin Waters sold 30K shares of common stock on March 7th in a total transaction size of $1.03M.

17:28 EST National Fuel CFO Karen Camiolo to retire, Timothy Silverstein to succeed - National Fuel announced a planned transition for the office of its treasurer and principal financial officer, effective May 1. Karen Camiolo has announced her intent to retire after nearly 29 years of service to the company. Timothy Silverstein has been appointed to succeed Camiolo as treasurer and principal financial officer of the company, effective with Camiolo's retirement.

17:23 EST Franklin Resources reports preliminary AUM $1.42T as of February 28 - Compared to $1.45T at January 31. This month's decrease in AUM reflected the impact of negative markets, partially offset by long-term net inflows inclusive of the previously disclosed $7.5B institutional mandate invested across fixed income strategies.

17:19 EST Ulta Beauty sees operating margin at 14%-15% over next few years - In its Q4 earnings call, the company states: "While stronger revenue growth has resulted in a meaningful improvement compared to pre-pandemic levels, our efforts to optimize our model through this period of disruption are delivering sustainable benefits. As a result, we are updating our expectations for operating margins. We remain confident we can deliver comp sales growth between 3% to 5% but now believe we can maintain operating margins between 14% to 15% of sales over the next few years. We believe the outlook for the beauty category is bright, and we are confident our strategic framework and strong financial foundation will enable us to drive long-term growth and shareholder returns."

17:10 EST Nano Dimension trading resumes

16:58 EST Nemaura Medical receives Nasdaq noncompliance notice - Nemaura Medical announced that on February 23, 2023, the company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC that the company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2022. Subsequently, on February 24, 2023, the company filed the Form 10-Q and regained compliance with Nasdaq Rule 5250(c)(1). On February 27, 2023, the Company received a notice from Nasdaq that, based on the Form 10-Q filing on February 24, 2023, Nasdaq determined that the company was in compliance with Nasdaq Rule 5250(c)(1) and the matter was closed.

16:52 EST PepsiCo exec sells $2.91M in common stock - In a regulatory filing, PepsiCo disclosed that its CEO of International Beverage, Ramkumar Krishnan, sold 16.8K shares of common stock on March 8th in a total transaction size of $2.91M.

16:39 EST El Pollo Loco sees FY23 capital expenditures $27M-$31M - Sees FY23 tax rate 26.5%. The company expects the opening of four to six new company-owned restaurants and eight to twelve new franchised restaurants.

16:38 EST Nano Dimension offers to acquire Stratasys for $18 per share - Nano Dimension (NNDM) announced that it has made a formal, non-binding offer to acquire Stratasys (SSYS) for $18.00 per share in cash. As expressed in Nano Dimension's announcement on July 18, 2022, the company views Stratasys as a strategic, complementary asset in the relatively mature polymer-based AM market segment. The Proposed Transaction would create a market leader with unparalleled portfolio of materials, software, and deep learning with a go-to-market strength in the form of sales channels. Nano Dimension's management has held constructive, informal discussions with Stratasys regarding the offer and the merits of the combination. Under the terms of the proposal, Nano Dimension, which has been the largest shareholder of Stratasys since July 2022 and currently owns approximately 14.5% of Stratasys' outstanding shares, would acquire the remaining shares of Stratasys for total consideration of approximately $1.1B in cash. The offer price reflects a premium of 36% to the unaffected closing trading price as of March 1, 2023, and a 31% premium to the 60-day VWAP through March 1, 2023. The proposal delivers immediate and certain value to Stratasys' shareholders and vastly strengthens the company's ability to capitalize on opportunities and navigate the challenges of the current environment. The execution of a definitive merger agreement between Nano Dimension and Stratasys would be subject to due diligence and approval by each company's Board of Directors and completion of the transaction would be subject to customary closing conditions, including receipt of required regulatory approvals and approval of Stratasys' shareholders.

16:33 EST Neurocrine announces results of published study on tardive dyskinesia - Neurocrine announced that new data from RE-KINECT real-world, observational, multicenter study of antipsychotic-treated patients with possible tardive dyskinesia, was published in the Journal of Patient-Reported Outcomes. The analysis assessed the effects of possible TD, defined as clinician-confirmed presence of abnormal involuntary movements, on patient health and social functioning. It demonstrated that it's important for clinicians to not only assess possible presence and severity of TD, but to also assess patient awareness of their own abnormal movements and the impact of these symptoms on the patients' overall wellness and ability to function to determine optimal management strategies.

16:31 EST Vandy Fartaj steps down as CIO of PennyMac Financial, PennyMac Mortgage - PennyMac Financial Services, Inc. (PFSI) and PennyMac Mortgage Investment Trust (PMT) announced that Vandy Fartaj is stepping down from his position as Senior Managing Director and Chief Investment Officer of both PFSI and PMT, in order to pursue other interests. "Vandy has been with Pennymac for nearly 15 years and I am thankful for his long tenure, tireless efforts and the numerous contributions he has made throughout our history, including helping us pioneer lender credit risk transfer transactions and the first mortgage servicing rights securitizations," said Chairman and Chief Executive Officer David Spector. William Chang has been appointed to the role of Senior Managing Director and Chief Capital Markets Officer for PFSI and Senior Managing Director and Chief Investment Officer for PMT.

16:31 EST W.P. Carey raises quarterly dividend to $1.067 per share - The dividend is payable on April 14 to stockholders of record as of March 31.

16:30 EST Vail Resorts lowers FY23 net income view to $282M-$328M from $321M-$396M - CEO Lynch said, "While we continue to expect strong demand from destination guests at our western North American resorts for the remainder of the season, we are lowering our guidance for FY23, primarily due to the significant weather disruptions at our Eastern U.S. resorts throughout the season-to-date period, as well as continued significant snowstorm disruptions at our Tahoe resorts. For FY23, we expect contribution margin from our 26 Eastern U.S. resorts, excluding an allocated portion of pass product revenue, to underperform initial expectations provided in September 2022 by approximately $43M, with the majority of the underperformance occurring after the peak holiday period...We now expect net income for FY23 to be $282M-$328M, and Resort Reported EBITDA between $831M and $859M. We estimate Resort EBITDA Margin for fiscal 2023 to be approximately 29.4%, using the midpoint of the guidance range...It is important to note that there continues to be uncertainty around the economic outlook and the impact that may have on travel and consumer behavior. The guidance assumes an exchange rate of $0.73 between the Canadian dollar and U.S. dollar related to the operations of Whistler Blackcomb in Canada, an exchange rate of $0.66 between the Australian dollar and U.S. dollar related to the operations of Perisher, Falls Creek and Hotham in Australia, and an exchange rate of $1.06 between the Swiss Franc and U.S. dollar related to the operations of Andermatt-Sedrun in Switzerland. Relative to our original September 2022 guidance, we estimate the movements in exchange rates will result in a 2023 guidance impact of approximately negative $6M for Resort Reported EBITDA."

16:25 EST Vail Resorts raises dividend 8%, increases share buyback authorization by 2.5M - The company's Board of Directors approved an 8% increase in the quarterly cash dividend to $2.06 per share beginning with the dividend payable on April 11 to shareholders of record as of March 27. The Board of Directors increased the company's authorization for share repurchases by 2.5M shares to approximately 3.5M shares.

16:24 EST Nano Dimension trading halted, news pending

16:20 EST AllianceBernstein reports preliminary AUM $665B as of February 28 - AllianceBernstein announced that preliminary assets under management decreased to $665B during February 2023 from $680B at the end of January. Firmwide net inflows were offset by market depreciation, resulting in a 2% decline in AUM. In the month of February, net inflows to Retail and Private Wealth were partially offset by modest Institutional net outflows.

16:18 EST Gap chief people officer Peters to leave at end of the year - Gap announced today that Mary Beth Laughton, President and CEO of Athleta is exiting the business, effective today. "We believe Athleta has incredible potential, but it has suffered from product acceptance challenges over the past several quarters. As we look to capitalize on this potential and remain competitive amidst a dynamic landscape, we believe now is the right time to bring in a new leader who can position Athleta for long-term success," Mr. Martin concluded. "I want to thank Mary Beth for her leadership and commitment to igniting the limitless potential of women and girls." While a search is underway, Gap Inc. Executive Chairman and Interim CEO, Bob Martin, will work closely with the Athleta team to lead through this transition until a new Brand President is identified. The company also announced that Sheila Peters, Chief People Officer, will leave the company at the end of the year. As a critical part of our transformation efforts, Sheila will continue in her role enabling our people and culture through experiences and practices needed to fuel our business, while helping to identify and transition her successor.

16:17 EST Oracle falls 5% to $82.50 after Q3 results

16:11 EST LivaNova receives FDA 510k clearance for Essenz Heart-Lung Machine - LivaNova announced it received U.S. Food and Drug Administration 510(k) clearance for its Essenz Heart-Lung Machine. With FDA clearance, LivaNova initiates the commercial launch of Essenz in the U.S. The Company also recently received approval for the Essenz HLM from Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency. Additionally, LivaNova is initiating a broad commercial release in Europe, following a successful limited commercial release that supported more than 200 adult, pediatric and neonatal patients in Europe. The Essenz HLM and Essenz Patient Monitor comprise the Essenz Perfusion System, which enables a patient-tailored perfusion approach rooted in data-driven decisions that improve both clinical workflows and quality of patient care during cardiopulmonary bypass procedures.

16:09 EST Tilly's sees FY23 capex at $15M-$20M

16:07 EST Oracle raises quarterly dividend 25% to 40c from 32c per share - This increased dividend will be paid to stockholders of record as of the close of business on April 11, with a payment date of April 24.

16:06 EST Virtus Investment reports February AUM $154.3B vs. $157.8M last month - Virtus Investment "reported preliminary assets under management of $154.3 billion as of February 28, 2023. In addition, the company provided services to $2.5 billion of other fee-earning assets, which are not included in assets under management."

15:06 EST Nano Dimension urges shareholders to disregard 'invalid' Murchinson meeting - Nano Dimension issued the following statement in response to a report issued by Institutional Shareholder Services in connection with the invalid shareholder meeting called by Murchinson: "Nano Dimension vehemently disagrees with ISS's recommendation. There is no valid meeting on March 20th, 2023 and Nano Dimension has not solicited any proxy cards. Therefore, we did not meet with ISS. Murchinson is attempting to convene an illegal meeting, thus disenfranchising retail shareholders that may not have had appropriate time to be notified and cast their votes. The ISS recommendation should be ignored, as it concerns an invalid shareholder meeting. We look forward to meeting with them to share our perspective, track record, and value creation strategy if and when a valid and duly called meeting will be held. The fact remains that Murchinson opted to flagrantly disregard protocols designed to protect the interests of all shareholders in favor of its one-sided and misleading campaign, failing to meet even the most basic requirements under applicable law. Murchinson has instead sought to launch an illegal shareholder meeting and associated campaign of personal attacks against the leadership of the company. As such, we filed a lawsuit in the Israeli court seeking a declaratory judgement that the Murchinson meeting is illegal. We are confident in the merits of the lawsuit and await the court's ruling. Nano Dimension's board of directors and management team will continue to act in the best interests of the company and all of its shareholders as we execute against our strategic plan, continuing to generate exceptional revenue growth and investing in the company to drive meaningful shareholder value. Since the arrival of the current management team in January of 2020, including the appointment of our Chief Executive Officer Yoav Stern, Nano Dimension's stock has increased by more than 15% and has materially outperformed peers under challenging market conditions. Nano Dimension has an independent and highly qualified Board that provides a robust oversight of the Company's proven management team and strategy. Our Board and governance structure protect shareholder interests, and the Board regularly evaluates its composition to ensure it has the right skills, expertise, and diversity of independent perspectives to guide Nano Dimension's strategic plan and create long-term shareholder value. Our Board currently consists of 9 highly qualified individuals - of which 7 are independent - with diverse skills and expertise across the 3D printing and digital-cloud-manufacturing industry, capital markets, corporate finance, and strategic business development in both the United States and Israel."

14:56 EST Baxter treatment of short bowel syndrome granted FDA orphan designation - Baxter Healthcare's treatment of short bowel syndrome was granted FDA orphan designation, according to a post to the agency's website. Reference Link

14:40 EST CollPlant Biotechnologies trading resumes

14:32 EST Ra Medical Systems announces granting of new U.S. patent - Ra Medical Systems announced that it has been notified of a new patent granted by the USPTO covering technology utilized in its VIVO product. The patent, number D980,420 S, entitled "Kit of Positioning Patches", was issued on March 7, 2023. The patent covers technology used in the disposable components of the VIVO product. David Jenkins, Executive Chairman of RMED, commented, "This newly issued patent joins a robust estate of intellectual property accumulated by our company. For the electrophysiology products, we have now have 36 issued patents and 15 application in process. Additionally, we have 15 patents and patent applications licensed into the company covering the VIVO technology. As a small medical device technology company, we believe the obtaining of IP is critical to our future and to the value of our company. We are quite pleased that another US patent has been granted to us."

13:51 EST SVB Capital II trading resumes

13:48 EST FTC acts to block deal combining Black Knight with IntercontinentalExchange

12:26 EST Norfolk Southern train derails in Alabama, no hazmat leaks - Alabama's Calhoun County Emergency Management Agency said that Norfolk Southern had a train derailment in the White Plains area. Initial reports indicate approximately 30 cars derailed. There are no injuries and no reports of leaks of hazmat and Norfolk Southern has responded and is "working closely with us," the agency added.

12:00 EST Kronos Worldwide falls -15.9% - Kronos Worldwide is down -15.9%, or -$1.74 to $9.17.

12:00 EST Solo Brands rises 17.2% - Solo Brands is up 17.2%, or 69c to $4.71.

12:00 EST Build-A-Bear rises 25.0% - Build-A-Bear is up 25.0%, or $5.15 to $25.73.

11:42 EST Turkcell trading resumes

11:11 EST Turkcell trading halted, news pending

10:52 EST ISS recommends Nano Dimension investors support Murchinson's proposals - Murchinson Ltd., the largest shareholder with approximately 5.2% of the outstanding shares of Nano Dimension Ltd., announced that Institutional Shareholder Services has recommended that shareholders vote to support all four of Murchinson's proposals, including the appointment of Murchinson's two independent nominees and the removal of four sitting directors - including Chairman Yoav Stern. In the report, ISS raised serious concerns around Nano Dimension's performance, governance and discount to NAV while supporting Murchinson's nominees: "The company's share price and operating performance, coupled with corporate governance deficiencies, indicate that change is necessary and that shareholders would benefit from enhanced independence on the board." Murchinson stated: "ISS has fully recognized change is urgently needed at Nano Dimension. It is clear that ISS - and we believe other shareholders - share many of the concerns we have expressed throughout our campaign about the Company's alarming performance, governance and disregard for the best interests of the Company and its shareholders. Notably, the report spells out the culpability of Chairman and CEO Mr. Stern in black and white. ISS's respected standing as both an expert in contested situations and as an objective third party should reinforce to shareholders that the call for change at Nano Dimension is the right one. As ISS notes, waiting means risking further value destruction. We strongly encourage fellow shareholders to vote today."

10:04 EST Cinedigm enters distribution agreement with SLING TV - Cinedigm Corp. announced a distribution deal with SLING TV for Midnight Pulp, The Country Network and AsianCrush, some of its top-performing free advertising-supported television channels, which are now available on Sling Freestream. The new agreement with SLING expands Cinedigm's partnership with the company to now include more than a dozen channels.

10:03 EST Anthony Hsieh nominates Steve Ozonian to loanDepot board - Anthony Hsieh, the Founder and largest voting stockholder of loanDepot, issued the following statement after of LDI's fourth quarter 2022 earnings call on Wednesday, March 8, 2023."Yesterday's earnings call was an important market update and reflects the extraordinary challenges facing all mortgage companies due to the unprecedented increase in interest rates. loanDepot cannot maintain the status quo if we are to succeed over the long-term. The Company's Board would benefit from a fresh perspective amidst these challenges to ensure we emerge stronger relative to our competition. I have nominated Steve Ozonian for election to the loanDepot board precisely for this reason. Steve's career of innovation in the homeownership business are important for the Company's thinking and strategy. I believe an important obligation as directors is to assess whether we have the most relevant experience and skills on the Board, particularly at a times where we are presented with the kinds of challenges the current market presents. I will vote my approximately 57% of combined voting power in support of his nomination. As I have previously stated, I have significant economic interest in the long-term performance of loanDepot. I do not take this decision lightly. I remain passionate about loanDepot's ability to deliver the dream of homeownership, and believe that Steve's experience and expertise will be important to loanDepot's long-term success."

10:00 EST Kronos Worldwide falls -13.6% - Kronos Worldwide is down -13.6%, or -$1.48 to $9.43.

10:00 EST Townsquare Media rises 17.5% - Townsquare Media is up 17.5%, or $1.27 to $8.53.

10:00 EST Solo Brands rises 21.6% - Solo Brands is up 21.6%, or 87c to $4.89.

09:50 EST InVivo Therapeutics trading resumes

09:47 EST First Republic falls -12.0% - First Republic is down -12.0%, or -$13.82 to $101.18.

09:47 EST Silvergate Capital falls -37.9% - Silvergate Capital is down -37.9%, or -$1.86 to $3.05.

09:47 EST Asana rises 17.2% - Asana is up 17.2%, or $3.07 to $20.87.

09:46 EST Charles Schwab drops 4% to $72.92 into 8.5M share block trade

09:40 EST JX Luxventure, China Southern partner to export pre-owned new energy vehicles - JX Luxventure (JXJT) has entered into a Memorandum of Understanding with China Southern Air Cross-Border E-Commerce (ZNHYY) in connection with exporting pre-owned new energy vehicles.

09:37 EST Harbor Custom Development expects engineering approval for Grandis Pond in Q4 - Harbor Custom Development announced that it anticipates receiving engineering approval in the fourth quarter of 2023 for the first phase of Grandis Pond, a 438-acre master-planned community in Blaine, Washington. In its current configuration, Grandis Pond is comprised of 872 single-family lots, 120 multi-family units and approximately ten acres of dedicated neighborhood commercial space. The project is located on the Washington Canadian border 33 miles from downtown Vancouver, British Columbia, a city that has a metro market population of nearly three million.

09:30 EST Motorsport Games says Le Mans Virtual reaches wider worldwide audience - Motorsport Games announced the latest report undertaken by YouGov Sport, the five-round Le Mans Virtual Series, which ran from September 2022 through to January 2023, recorded growth in TV and digital audience figures in almost every area. The virtual racing series took place over five months on extremely detailed and realistic representations of iconic and well-known circuits in Bahrain, Monza, Spa and Sebring, with the finale to the season being held at the iconic Circuit des 24 Heures in Le Mans, France. The 24 Hours of Le Mans Virtual on 14/15th January brought together 45 LMP and GTE cars with 180 drivers from 41 different countries. Teams battled it out for a $250,000 series prize pool across the five rounds, with the competitors racing on 164 simulators worldwide - representing manufacturers such as Alpine, BMW, Ferrari, Mercedes, Peugeot and Porsche.A n impressive, cumulative, audience reach of over 8.5 million via TV, OTT and digital audiences was recorded for the 24 Hours of Le Mans Virtual in a recent report by YouGov Sport.

09:21 EST Ideal Power adds automotive supplier to B-TRAN test, evaluation program - Ideal Power has been collaborating with a global Tier 1 automotive supplier. The automotive supplier has now entered into an agreement with Ideal Power to test and evaluate B-TRAN devices for its electric vehicle inverter, bidirectional charging, and circuit protection applications.

09:16 EST Qualtrics, Twilio team to create 'richer customer profiles' and actionable ideas - Qualtrics (XM) and Twilio (TWLO) are expanding their partnership and introducing a new no-code connector that allows real-time data sharing and integration between the Twilio Segment customer data platform CDP and Qualtrics' Experience iD, XiD . The combined view of operational engagement data like content engagement, purchases, user logins and cart abandonments in Twilio Segment with qualitative data like customer satisfaction and effort scores in XiD creates richer customer profiles and more actionable insights. Personalization is an imperative for businesses today. Recent research, commissioned by Twilio, found that 62% of consumers expect personalization, saying that a brand will lose their loyalty if their experience is not personalized - meanwhile, 49% will become repeat buyers if personalization is offered. Empowered by this new integration, brands can use a unified combination of customer behavior data and overall sentiment data, to create differentiated, personalized experiences that exceed consumer expectations. "The combination of data from Twilio Segment and Qualtrics XiD has unlocked new visibility into our customers' experience, removing silos in our data," said Courtney Anderegg, Lead Customer Insights Analyst at Imperfect Foods. "With detailed and consistently up-to-date customer profiles, we were able to personalize outreach and improve the quality of our product for our customers."

09:16 EST Coursera sees positive adjusted EBITDA in 2024 - Coursera sees long term revenue growth 25%-30%. Sees long term gross margin 58%-63%. Sees long term adjusted EBITDA margin 15%-20%. "In 2024, we expect our Degrees segment revenue growth will accelerate to more than 25% year-over-year, reflecting strong enrollment trends in programs designed for working adults," said Ken Hahn, Coursera's CFO. "We believe our differentiated business model, including multiple levers of growth with operational efficiencies, will allow us to achieve positive Adjusted EBITDA in 2024 while investing in our long-term strategy."

09:08 EST Verizon offers one year of Netflix for free through its +play subscription hub - Starting March 12 and for a limited time, Verizon (VZ) wireless, 5G Home and LTE Home customers can get one year of Netflix's (NFLX) Premium plan for free through +play, Verizon's subscription hub. The Netflix offer gives customers $240 in annual savings and will only be available for a limited time.

09:07 EST CNS Pharmaceuticals enrolls first patient in Switzerland for Berubicin trial - CNS Pharmaceuticals announced that the first patient in Switzerland has been enrolled in the company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The company has opened 40 clinical trial sites of the 59 sites selected across the U.S., Italy, France, Spain, and Switzerland. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have reached the primary endpoint. Enrollment will not be paused during this interim analysis. Berubicin is currently being evaluated in a potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM. The primary endpoint of the study is Overall Survival. The FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin. Additionally, the company has received Orphan Drug Designation from the FDA which may provide seven years of marketing exclusivity upon approval of an NDA.

09:07 EST CareCloud to showcase RCM solution at MGMA Conference - CareCloud announced its participation at the Medical Practice Excellence: Financial and Operations Conference hosted by the Medical Group Management Association. The event will take place from March 19-21 at the Hyatt Regency Grand Cypress in Orlando, Florida, and CareCloud will be exhibiting in booth 313.CareCloud will showcase its comprehensive suite of technology-enabled services and solutions at booth 313, including its powerful revenue cycle management solution, Concierge. Concierge can help healthcare providers improve cash flow, reduce denials and rejections, enhance the patient experience, and increase revenue. By leveraging advanced technology and automation to streamline and optimize the healthcare revenue cycle, Concierge can significantly reduce errors and identify missed revenue opportunities, leading to improved financial sustainability for healthcare organizations.

09:06 EST Tenable Holdings announces new capabilities for Tenable OT Security - Tenable announced new capabilities within Tenable OT Security, providing broader protection for operational technology, critical infrastructure and industrial control systems, regardless of size of deployment or configuration of environment. The new functionality keeps the CISO's organization front and center, making it even easier to secure and maintain governance of the entire attack surface, using the same tools and processes across their infrastructure, be it OT, IT, IoT, cloud or other platforms.

09:05 EST Rumble issues statement on ESG matters - Rumble announced the publication of a statement that details the company's view on environmental, social, and governance matters. "At Rumble, we strongly believe that the pursuit of our mission of restoring a free and open Internet leads to a societal benefit that is not captured by existing ESG frameworks, standards, or metrics. By pushing back against cancel culture and creeping censorship, we help facilitate a free exchange of ideas between our content creators and users. We believe that remaining true to our goals is the best way to fulfill our fiduciary duties to our shareholders. We devote our time, effort, and capital to maximizing shareholder returns by developing and continuously improving our product, growing our user base, and attracting top content creators, all while pursuing our mission of promoting the free expression of ideas. We do not attempt to win approval from outside groups that seek to advance goals or agendas beyond staying focused on our mission and producing returns for our shareholders. We encourage our stakeholders to continue to judge us by the returns we deliver as we work to restore a free and open Internet."

09:04 EST General Motors announces voluntary separation program - In a regulatory filing, General Motors announced a voluntary separation program in an effort to accelerate the normal attrition process and the resulting cost savings. "Under the terms of the VSP, eligible employees who choose to leave the Company will be offered a combination of lump sum payments and other compensation based on their years of service. In connection with the VSP, the Company expects to incur up to $1.5B of pre-tax employee separation charges, which will be substantially all cash-based, and up to $300M in pre-tax, non-cash pension curtailment charges. The final amount of the charges will be based on the composition of employees who elect to participate in the VSP. The Company anticipates that substantially all of these charges will be considered special for EBIT-adjusted, EPS-diluted-adjusted, and adjusted automotive free cash flow purposes. The Company expects to incur the majority of these charges in the first half of 2023, with some additional costs incurred throughout the remainder of the year, and to make substantially all of the cash payments by the end of 2023."

09:03 EST Euronet's Ria Money Transfer partners with ACLEDA - Ria Money Transfer, a business segment of Euronet, and ACLEDA Bank announced a partnership that broadens cross-border money transfer services available to and from Cambodia. This expansion of Ria's network includes convenient services such as cash payments, cash collection in both KHR and USD and account deposits. Partnering with ACLEDA expands Ria's presence in Cambodia, adding almost 300 cash pickup and payout locations for a total of 4,318 locations in the country. "Remittances continue to be a vital source of income for people in many countries, and at Ria, we are committed to helping people who are living and working far from home have access to the money transfer services they need to build a better everyday life," said Juan Bianchi, CEO of Euronet's Money Transfer segment. "This partnership enables us to better serve our customers and strengthen our presence in the region."

09:02 EST Shuttle Pharmaceuticals signs new manufacturing agreement for Ropidoxuridine - Shuttle Pharmaceuticals has signed an agreement with the University of Iowa Pharmaceuticals for formulation development and clinical batch manufacture of drug capsules of Ropidoxuridine. This is expected to be the final step required in the drug manufacturing process for use in Shuttle Pharma's upcoming Phase II clinical trial evaluating Ropidoxuridine in combination with radiation therapy for the treatment of glioblastoma. Shuttle Pharma has worked with TCG GreenChem to complete the campaign to manufacture 25 kg of the drug product for Ropidoxuridine, and approximately 10,000 capsules, to complete the Phase II trial. Shuttle Pharma is preparing the Investigational New Drug application for the study with an expectation of final submission to the FDA at the end of Q2. UI Pharmaceuticals is a university-affiliated CDMO offering pharmaceutical product development, manufacturing and analytical services.

08:53 EST GE Aerospace sees Leap engine program to be profitable by mid-decade

08:51 EST HUMBL launches 'HUMBL Chat' audio rooms - HUMBL announced the launch of its "HUMBL Chat"audio rooms integration, providing HUMBL Social users with the ability to create voice chat rooms ranging from individuals and small rooms, to large groups of up to 1,000 people. HUMBL Chat capabilities include peer-to-peer voice rooms with clear, low-latency connections. HUMBL Chat is also pilot testing the ability for users to record audio rooms and save them as .mp3 files, which can be used for archives, interviews, interactive podcasts and transcriptions.

08:50 EST InVivo Therapeutics trading halted, news pending

08:43 EST SKYX Platforms acquires 50% of Bailey Street Home for $225,000 in cash - SKYX Platforms has acquired Bailey Street Home, a $5M revenue, profitable, strategic e-commerce private label lighting website. SKYX has paid $225,000 in cash for 50% of the e-commerce lighting website company, while the other 50% is owned by Belami, Inc., the strategic e-commerce company that SKYX has already signed an agreement to acquire. The $5 million in 2022 annual revenues from the e-commerce private label brand is in addition to the $86 million in 2022 annual revenues from Belami. The acquisition of this strategic e-commerce lighting website company will serve as another marketing and growth platform for SKYX, providing additional distribution to both professional and retail channels for SKYX's revolutionary Plug & Play technology for lighting and ceiling fan installations.

08:41 EST BK Technologies receives purchase order for InteropONE PTToC service - BK Technologies has received its first purchase order for its InteropONE PTToC service from a large public safety agency in a top five U.S. metropolitan market.

08:40 EST Predictive Oncology issues letter to shareholders - Predictive Oncology issued the following letter to shareholders: "...Market Conditions. The rapidly growing global AI drug discovery market size was valued at USD 1.1 billion in 2022 and is expected to increase at a compound annual growth rate of 29.6% from 2023 to 2030 to nearly $7 billion. The growing demand for the discovery and development of novel drug therapies and increasing manufacturing capacities of the life science industry are driving the demand for AI solutions in the drug discovery processes...The adoption of AI solutions in the clinical trial process eliminates possible obstacles, reduces clinical trial cycle time, and increases the productivity and accuracy of the clinical trial process. Therefore, the adoption of these advanced AI solutions in drug discovery processes is gaining popularity amongst many life science industry stakeholders... Amongst the different phases of drug development, preclinical testing is associated with the highest failure rate, and is therefore extremely costly to biopharma companies. Through the adoption of AI solutions, the preclinical testing phase can be optimized to minimize costs. AI-based models are implemented to accurately analyze human physiological responses and eliminate experimental costs... Financial Overview. Balance Sheet: Predictive Oncology holds a strong cash position providing approximately 18 months of liquidity and is not currently in need of additional funding. The cash balance is further supported by a large warrant position, the exercise of which may represent an additional source of capital, and combined with the anticipation of increased revenue over the next 2 -3 years, we believe that this cash position can be managed and maintained... NASDAQ Deficiency: In May 2022, Predictive Oncology received a price per share deficiency notification. The Company filed an extension to remedy that deficiency in November 2022. The Company now has until May 8, 2023 to attain a minimum $1 trading price per share over ten consecutive trading days... Stock Buy Back: The Company's Board of Directors believes that the Company value and prospects are not accurately reflected in the trading price of its common stock, and may consider repurchasing shares of its common stock when it is able and advisable to do so in compliance with securities laws... Plans and Measures. The Senior Management and Board of Directors of Predictive Oncology have been entirely focused on addressing the most critical issues facing the Company over the past few months: compliance with Nasdaq's listing requirements, stabilizing the Company's equity, restoring investor confidence, negotiating agreements and executing new customer contracts. Throughout this entire process, Management has endeavored to be completely transparent and has maintained open lines of communication with shareholders, brokers and potential new investors. We have responded, and continue to respond, to all emails, telephone calls and other requests for information, and we have proactively reached out to new investors and have participated in multiple investor and biopharma conferences"

08:37 EST Sight Sciences launches Ergo-Series of OMNI Surgical System - Sight Sciences announced the United States launch of the Ergo-Series of the OMNI Surgical System, a technology that facilitates surgeons' ability to perform minimally invasive, implant-free glaucoma procedures in adults with primary open-angle glaucoma. The OMNI Surgical System enables a minimally invasive glaucoma surgery that addresses all three known points of resistance in the aqueous outflow system: the trabecular meshwork, Schlemm's canal, and the collector channels. It can be used before, in combination with, or following cataract surgery. The new features of the Ergo-Series include: Improved Handle Ergonomics: New enhancements enable surgeons to more easily rotate and position the cannula tip within Schlemm's canal with precise finger rotations versus wrist adjustments. Simplified Viscoelastic Preparation: The handle's viscoelastic luer connector is now removable and detaches when the viscoelastic cartridge is removed, resulting in more clearance with the surgical microscope. New Cannula Tip Design: The Ergo-Series cannula tip has a new profile that enables gentle and precise access to Schlemm's canal while continuing to enable full 360-degree catheterization associated with the OMNI procedure. The Ergo-Series of the OMNI Surgical System is expected to be available outside the United States later this year.

08:35 EST MamaMancini's appoints Romig to board of directors - MamaMancini's announced the appointment of consumer and digital technology executive Shirley Romig to its Board of Directors. Shirley brings more than 20 years of operations and public company corporate governance experience to the MamaMancini's Board of Directors. Shirley most recently served as CEO of Mixo, a startup building a new social commerce platform that simplifies digital food content creation.

08:33 EST Wheels Up reports active Members increased 5% year-over-year to 12,661 in total - Live Flight Legs decreased 5% year-over-year to 19,308 in total.

08:28 EST PayPal CEO says seeing 'strength that's beyond what we expected' in Q1-to-date - While speaking last night at the Morgan Stanley Technology, Media & Telecom Conference, PayPal CEO Dan Schulman stated in part, according to a transcript of the event: "In terms of kind of the economy and e-commerce, I said a month ago when we reported Q4 that the quarter was off to a strong start. And here we are about a month later, and I would reiterate that again. I think across our business, we're seeing strength that's beyond what we expected. Both branded checkout is accelerating. Unbranded, it's doing quite well. So we're either beginning to see the beginning of a turn of e-commerce. The inflation cooling slightly. Maybe discretionary spend coming back. Maybe our products really taking an impact in the market."

08:25 EST Kratos Defense introduces OpenSpace vStar solution for Satcom hubs - Kratos Defense & Security Solutions introduced the first of its OpenSpace vStar solutions designed to modernize satellite communications ground systems and enable them to interoperate smoothly with terrestrial and cellular networks. Part of Kratos' OpenSpace Platform, vStar products are virtual replacements for the traditional hardware-based hubs used in satcom today. As software, vStar offers dramatic advantages over traditional hubs, including simultaneous support for point-to-point and star topologies, multi-mission operations, dynamic configuration and touchless deployment within cloud and hybrid environments.

08:24 EST PowerFleet to acquire Movingdots, terms not disclosed - Powerfleet has signed a definitive agreement to acquire Movingdots, a provider of insurance telematics and sustainable mobility solutions based in Bremen, Germany, and a subsidiary of one of the world's leading re-insurers, Swiss Re. Movingdots, in partnership with Swiss Re's Automotive and Mobility unit, has spent nearly a decade designing and perfecting data science algorithms with primary insurers to provide risk-based drive style analytics for fleets and personal auto risk. Backed with actuarial insights, Movingdots enables data-driven insurance propositions for insurers, car manufacturers, and mobility platform players worldwide. By focusing on customers' safety and security needs, and by providing transparent and comprehensive monitoring, Movingdots combines insurance analytics with artificial intelligence technology to derive an individual risk assessment. Movingdots has been looking for the right strategic growth partner to deliver these precisely architected insurance solutions to the global market in a sustainable, profitable, and scalable way. The acquisition is expected to close in the first quarter of 2023. Following the completion of the acquisition, all Movingdots customers will continue to receive exceptional service from the Movingdots team.

08:22 EST Reed's expands Whole Foods Market distribution with multiple new SKUs - Reed's announced that it has expanded its portfolio across select Whole Foods Market locations nationwide. "We are excited to expand our collaboration with Whole Foods Market after so many successful years working together," said Norman Snyder, CEO of Reed's. "Whole Foods Market is a leader in the natural and organic food space committed to high quality products that contain better ingredients. We look forward to our joint success in serving the natural-focused consumer for years to come."

08:22 EST Reneo Pharmaceuticals to present REN001 data at SIMD meeting - Reneo Pharmaceuticals announced that the company will present a preclinical poster at the Society for Inherited Metabolic Disorders, SIMD, Annual Meeting, being held in Salt Lake City, Utah, Mar. 18-21, 2023. Presentation: "PPARdelta Agonist REN001 Improves Mitochondrial Function in Skeletal Muscle: A Potential Treatment for Primary Mitochondrial Myopathies." The poster highlights the findings of pharmacological and biochemical studies which demonstrate that mavodelpar is a potent and selective agonist of peroxisome proliferator-activated receptor delta, resulting in increased fatty acid metabolism. Further, mavodelpar activation of PPARdelta in mice was found to increase expression of genes involved in fatty acid metabolism, oxidative phosphorylation, and mitochondrial biogenesis.

08:20 EST Agrify enters agreement to modify credit facility - Agrify Corporation announced it has signed a definitive agreement with its institutional lender to amend its existing credit facility. Key Transaction Terms: Significant reduction in outstanding principal from approximately $32 million to approximately $11.675 million after the repayment and exchange; Elimination of working capital and restricted cash covenants to allow the Company more flexibility to pursue future growth; Revision of merger & acquisition covenant to permit acquisitions using stock as consideration ; Expected interest expense savings of approximately $1 million annually. Pursuant to the terms of the Securities Exchange Agreement by and between Agrify and the Lender, dated as of March 8, 2023, at closing Agrify will exchange $10.0 million of the balance of the senior secured promissory note issued to the Lender in August 2022 with an aggregate original principal amount of $35.0 million for a new senior secured convertible note with an aggregate original principal amount of $10.0 million, and prepay in cash approximately $10.3 million of the remaining balance of the August 2022 Note. After the repayment and exchange, the remaining principal of the August 2022 Note will have been reduced from approximately $32 million to approximately $11.67 million. Pursuant to the Exchange Agreement, Agrify and the Lender have agreed to amend the terms of the August 2022 Note to allow for the removal of working capital and restricted cash covenants and a modification of the merger and acquisition restriction to permit acquisitions using stock as consideration. The Convertible Note will be convertible at the option of the Lender at any time before its maturity date in August 2025. The conversion price will be a fixed price of $0.3820 per share, subject to customary adjustments for stock splits, rights plans, spin-offs, dividends, and similar transactions, which represents the Minimum Price as defined pursuant to applicable Nasdaq rules. The Lender may not exercise its conversion rights to the extent the resulting conversion would result in the Lender beneficially owning more than 4.99% of Agrify's outstanding shares of common stock, which percentage may be increased to up to 9.99% under certain circumstances. Should Agrify raise at least a further $8.0 million in equity before August 19, 2023, the Lender will be prohibited from exercising its right to redeem the August 2022 Note or the Convertible Note in August 2023. The Exchange Agreement provides that the Lender may, at its option, elect to exchange an additional $10.0 million in principal amount under the August 2022 Note for an additional $10.0 million principal amount convertible note on August 19, 2023. Agrify will also agree to repay at least a further $3.0 million of the August 2022 Note before December 31st, 2023, and any cash sweep from future equity raises will count towards the repayment. The principal amounts of the August 2022 Note and the Convertible Note will be payable on their respective maturity dates, provided that the Lender will be entitled to a cash sweep of 30% of any proceeds received by Agrify in connection with any At-The-Market equity financing, which will reduce the outstanding principal amount under the respective notes. The Lender will be entitled to a cash sweep of 20% for all other equity issuances. Both the August 2022 Note and the Convertible Note will earn interest at a 9.0% annualized interest rate, with interest to be paid monthly in cash.

08:19 EST Kaival Brands signs agreement with national broker, expand access to Bidi Vapor - Kaival Brands Innovations announced that it has entered into a sales broker agreement with a prominent national broker to expand access to Bidi Vapor products from its current foundation of convenience-store distribution into new retail channels, including dollar, grocery and mass-merchandisers. "As we look to push distribution into more channels beyond the convenience-stores, we are excited to announce a new agreement that gives us potential access to over 40,000 new locations," said Eric Mosser, President & Chief Operating Officer of Kaival Brands. "We believe this agreement, along with our recent announcement of other new distribution agreements, further validates our reputation as a good actor providing adult consumers with the highest quality vape experience possible, and we look forward to working with all of our commercial channel partners to expand our revenue opportunities."

08:18 EST Sermonix announces initiation of Phase 3 ELAINE-3 study of lasofoxifene - Sermonix Pharmaceuticals and Guardant Health (GH) announced the initiation of a registrational Phase 3 clinical study comparing targeted lasofoxifene, which Sermonix licensed globally from Ligan (LGND) in combination with the CDK 4/6 inhibitor abemaciclib versus fulvestrant plus abemaciclib in pre- and post-menopausal subjects with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation. This global randomized study will enroll 400 subjects with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation, who have progressed on palbociclib or ribociclib plus an aromatase inhibitor and up to one line of chemotherapy. Subjects will be randomized 1:1 to receive either lasofoxifene or fulvestrant, and both groups will also receive 150 mg of abemaciclib twice daily. Study subjects will be prospectively screened for an ESR1 mutation using the Guardant360 CDx liquid biopsy, a next generation sequencing-based test that detects genomic alterations using circulating tumor DNA from blood. Eli Lilly and Company - which provided abemaciclib for the ELAINE-2 study - has entered into a new clinical trial collaboration and drug supply agreement with Sermonix and will provide abemaciclib for the ELAINE-3 study. The primary efficacy endpoint is progression-free survival. Key secondary endpoints include overall response rate and overall survival. Additional secondary endpoints to be assessed include clinical benefit rate, duration of response, time to disease recurrence, time to chemotherapy, quality of life, patient reported outcomes on vaginal and sexual health, and safety. Sermonix anticipates dosing the first subject in the first half of 2023.

08:14 EST LanzaTech achieves RSB certification - LanzaTech has achieved RSB certification.In early January 2023, LanzaTech successfully completed the rigorous requirements to demonstrate its compliance with the requirements of the RSB Global Standard. By achieving this certification, LanzaTech builds upon its commitment to delivering high quality products, while demonstrating high levels of social responsibility and environmental sustainability. LanzaTech's customers can have confidence in the verified positive impacts of the certified materials, demonstrated by their compliance with RSB's robust and independently verified sustainability requirements.

08:12 EST Certara adds deep learning capabilities to D360 - Certara is adding deep learning capabilities to D360. The addition of novel A.I. will enable discovery scientists to integrate multiple structured and unstructured data sources and substantially enhance predictions and analysis of content related to small molecules and biologic drugs for accelerated, high confidence decisions.

08:11 EST Pyxis Tankers to sell Pyxis Malou for $24.8M in cash - Pyxis Tankers agreed to sell the vessel Pyxis Malou, 2009 built 50,667 dwt. product tanker, for a sale price of $24.8 million in cash to an unaffiliated buyer located in the United Kingdom. Completion of the vessel sale, which is subject to customary closing conditions, is scheduled to occur by March 31, 2023. After the repayment of the outstanding indebtedness for this vessel and the payment of various transaction costs, the Company expects to receive cash proceeds of approximately $18 million, which would be used for general corporate purposes, including additional debt repayment. Assuming scheduled completion of the sale at March 31, 2023, the Company expects to recognize a non-cash gain from asset disposition of approximately $8 million or approximately $0.75 per outstanding common share

08:10 EST LPL Financial announces Scott Glasson joins Linsco - LPL Financial announced that financial advisor Scott Glasson has joined LPL's employee advisor channel, Linsco by LPL Financial, to launch his practice, Glasson Financial Powered by LPL Financial. He reported having served approximately $120 million in advisory, brokerage and retirement plan assets, and joins LPL from Wells Fargo Advisor. Glasson will have an office in the Linsco suite of LPL's San Diego campus.

08:09 EST Vertex says FDA clears IND for VX-264 with potential to treat type 1 diabetes - Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has cleared the Investigational New Drug Application, IND, for VX-264, a stem cell-derived, fully differentiated pancreatic islet cell therapy encapsulated into a Vertex-developed, immunoprotective device with the potential to treat type 1 diabetes or T1D . The VX-264 program does not require the use of immunosuppression, which may broaden the population of people with T1D that this investigational therapy could reach. Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023 to study the safety, tolerability and efficacy of VX-264 in patients with T1D. The company previously received approval from Health Canada on the Clinical Trial Application for VX-264, and the Phase 1/2 trial is ongoing in Canada. "VX-264 uses the same stem cell-derived pancreatic islet cells as our VX-880 program where we've already demonstrated proof-of-concept, with the addition of a proprietary immunoprotective device that allows us to eliminate the need for immunosuppression," said Bastiano Sanna, Ph.D., Executive Vice President and Chief of Cell and Genetic Therapies at Vertex. "We are excited to see our second program in T1D advancing into the clinic and look forward to bringing transformative, if not curative, therapies to T1D patients who are waiting."

08:05 EST Prime Medicine expects cash to fund operations into 2025 - Based on its current operating plans, Prime Medicine expects that its cash, cash equivalents and short-term investments as of December 31, 2022 will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into 2025.

07:52 EST Arch Resources' AC5 system receives dedicated HCPCS billing code - Arch Therapeutics announced that the Centers for Medicare and Medicaid Services established a new Level II Healthcare Common Procedure Coding System code dedicated to the Company's AC5(R) Advanced Wound System. The new HCPCS code, "A2020," will become effective on April 1, 2023, creating a new pathway for reimbursement of AC5. The HCPCS code is expected to improve the ability of providers to charge CMS and other insurers for AC5 used in doctors' offices, wound care clinics, hospital outpatient departments and ambulatory surgical centers.

07:50 EST General Electric to have 'high growth' this year, Culp says

07:48 EST KP Tissue sees Q1 Adjusted EBITDA similar to 4Q22 - The company said, "Looking ahead to the first quarter of 2023, our price increases are in place, and we believe inflationary pressure has stabilized, while our operating efficiency continues to gain traction and we are tightly managing our discretionary spending. As a result, we expect Adjusted EBITDA in Q1 2023 to be similar to Q4 2022 and to significantly exceed Q1 2022."

07:40 EST Laser Photonics expands Service Partner Network program - Laser Photonics announced the expansion of its Service Partner Network program.The SPN is a fast-track way for individual business owners and small companies to start a new and exciting laser cleaning business with support from LPC. SPN Members benefit from access to financing for LPC equipment, high quality leads and sales opportunities for services and LPC equipment. Members have access to a vast array of entrepreneurial opportunities including providing laser cleaning services in the corrosion, rust and oxide removal, coating and overspray, grease and rust, and the marine boat industry. Applications can include biofilm and graffiti removal, mold and commercial grill cleaning, among others. LPC projects an additional 5 to 10 new service partners in major markets and key locations near automotive, aerospace, shipbuilding, nuclear and military facilities in 2023.

07:38 EST Titan Medical announces decision of Nasdaq hearings panel to delist shares - Titan Medical announced that it has received a decision of the Nasdaq Hearings Panel advising the Company that effective at the open of business on March 10, 2023, the Company's common shares will be delisted from The Nasdaq Stock Market. On December 30, 2021, Nasdaq Listing Qualifications staff issued the Company a deficiency notice citing its failure to comply with the minimum bid price requirement under Listing Rule 5550(a)(2). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until June 28, 2022, to regain compliance with the Rule. On June 29, 2022, the Company was provided an additional 180 calendar day compliance period, or until December 26, 2022, to demonstrate compliance with the Rule. On December 27, 2022, Staff notified the Company that it had determined to delist the Company as it did not comply with the Rule for listing on Nasdaq. On January 3, 2023, the Company requested a hearing, which was held on February 16, 2023, staying any delisting pending the issuance of the Panel's decision. Trading in common shares on Nasdaq will be suspended effective at the opening of business on March 10, 2023 and Nasdaq will complete the delisting by filing a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission, after applicable appeal periods have lapsed. The Company is listed on the Toronto Stock Exchange and Nasdaq's delisting notice does not impact the Company's listing on the TSX. The Company expects that its common shares will be eligible for quotation on the OTC Markets with the opening of business on March 10, 2023.

07:37 EST Rio2 Limited outlines plans for completion of Fenix Gold financing - Rio2 Limited is providing an outline of its plans to complete the financing for the construction of the Fenix Gold Project in Chile. The plan includes appointing an independent financial advisor, completing a Feasibility Study on the development of the Fenix Gold Project, reviewing and restructuring the precious metals purchase agreement with Wheaton Precious Metals International Ltd and re-engaging with lenders for the senior project debt facility of the Project construction financing. Rio2 has appointed Endeavour Financial to provide financial advisory services with respect to the financing and construction of the Fenix Gold Mine. Endeavour will work closely with Rio2 board and management in developing the optimum financing solution for the Fenix Gold Project given the Project's current status. Endeavour will provide a full-service approach to the financial advisory, which includes the review and restructuring of the existing precious metals purchase agreement, technical guidance during the completion of the Feasibility Study and dealing with lenders on the debt component of the financing. An updated Pre-Feasibility Study was prepared for the Fenix Gold Project in August 2019 and amended and restated on August 3, 2021. Since that date, and over the course of H1 2022, the Company completed detailed engineering and updated cost estimates for the purpose of financing discussions with lenders for the construction of the Project. Discussions with lenders were halted on July 5, 2022, when the approval of the Project's Environmental Impact Assessment was formally declined by the Chilean Government. Given the Project's current status, the Company has decided to incorporate the detailed engineering into a new study and update operating and capital costs to reflect today's cost environment. The gold price will also be updated to a more appropriate level, given the August 2019 study was based on a gold price of $1,250. This new study will be completed to a Feasibility level and is expected to be completed and published by the end of Q2, 2023. The Feasibility Study will be a key document for consideration by the Project's potential lenders.On March 29, 2022, Rio2 announced that it had received a deposit payment of US$25,000,000 from Wheaton Precious Metals in connection with the previously announced precious metals purchase agreement on Rio2's Fenix Gold Project in Chile. Under the Gold Stream, WPMI will purchase 6.0% of the gold production until 90,000 ounces of gold have been delivered, thereafter dropping to 4.0% of the gold production until 140,000 ounces of gold have been delivered, after which the Gold Stream will reduce to 3.5% of the gold production for the life of mine from the Fenix Gold Project. In addition, WPMI will make ongoing production payments for gold ounces delivered equal to 18% of the spot gold price until the value of gold delivered to WPMI less the production payments is equal to the total upfront consideration payable by WPMI under the Gold Stream of US$50 million, at which point the production payment will increase to 22% of the spot gold price. As part of the agreement, a second deposit of US$25,000,000 was to be paid to Rio2 following the receipt of the EIA approval for the Fenix Gold Project, and subject to the satisfaction of certain other customary conditions. As the approval of the EIA was declined by the Chilean Government on July 5, 2022, the timing and completion dates of the construction and eventual production of the Fenix Gold Project are currently unknown. Given this uncertainty, Rio2, in close consultation with Endeavour Financial, is planning to revise and restructure the agreement with WPMI as soon as practicable. Discussions with potential lenders were well advanced prior to the negative EIA decision by the Chilean Government on July 5, 2022. Technical due diligence was almost completed by independent experts acting on behalf of the lenders before July. On receipt of the negative EIA decision, it was decided with the lenders that the due diligence work be put on hold, with reactivation expected once the planned Feasibility Study is completed. Despite the suspension of activities pertaining to the construction of the Project, Rio2 is encouraged that lenders are still showing interest in participating in financing the Fenix Gold Mine construction.

07:36 EST Holley sees FY23 revenue $625M-$675M, consensus $679.16M - Sees FY23 adjusted EBITDA of $108-$122M. Sees FY23 interest Expense in the range of $60-$65M.

07:34 EST Soligenix submits Type A Meeting Request to FDA for HyBryte - Soligenix announced that the company has submitted a Type A Meeting Request to the United States FDA to discuss the contents of a refusal to file letter previously issued by the FDA regarding the company's new drug application for HyBryte in the treatment of early stage cutaneous T-cell lymphoma, a rare cancer, where it has successfully demonstrated statistically significant results in a Phase 3 clinical trial. The Type A Meeting is expected to occur approximately 30 days from the FDA's receipt of the meeting request.

07:30 EST Helius Medical announces authorization from Health Canada to market PoNS - Helius Medical Technologies announced that Health Canada has expanded the indication for Portable Neuromodulation Stimulator, PoNS, to include use as a short term treatment of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. PoNS is already authorized in Canada for use as a short term treatment of chronic balance deficit due to mild to moderate TBI and gait deficit due to mild and moderate symptoms from MS. "An estimated 878,000 Canadians are currently living with stroke, with more than 89,000 new strokes occurring each year. Walking impairment is a major source of post-stroke disability and we're thrilled that patients suffering gait deficit due to stroke can now have access to this important therapy," said Helius President and Chief Executive Officer Dane Andreeff. "PoNS has been commercially available in Canada since 2019 for MS and TBI, and it's gratifying to know Health Canada has found that PoNS Therapy can provide significant and clinically meaningful gait improvement also in stroke patients, suggesting that PoNS Therapy provides an effective therapeutic benefit regardless of the underlying condition."

07:28 EST West Red Lake Gold completes acquisition of Rowan Property - West Red Lake Gold Mines has closed the acquisition to increase its ownership in the Rowan Property from 72% to 100% by purchasing the remaining 28% interest from Evolution Mining. The Rowan Property is the most advanced property within the West Red Lake Gold Project, a 3,100-hectare area consisting of three properties. The Rowan Property is located north of Red Lake and borders Evolution's Red Lake gold complex. In consideration for the Acquisition, the Company paid CAD $250,000 and issued 3,645,000 common shares of WRLG to Evolution. Evolution will retain a 2.5% NSR on the Rowan Property. The Company also issued an aggregate of 182,250 common shares to certain third parties as a success fee. On closing, Evolution holds a 6.53% interest in West Red Lake Gold. Insiders and Evolution hold an aggregate of 39.15% of the issued and outstanding common shares of the Company, including Frank Giustra who holds 18.10% and Accilent Capital Management Inc. which holds 13.56%. All securities issued in connection with the Acquisition and success fees are subject to a four month and one day statutory hold period expiring on July 9, 2023.

07:26 EST Ree Automotive names authorized dealers for U.S. - REE Automotive (REE) announced the names of the first US dealers that will be offering Powered by REE EVs to end customers looking to electrify their commercial fleets, as part of REE's go-to-market approach of signing authorized dealers. Initial deliveries to these dealers are slated to begin in Q4 2023. The dealers include the previously unnamed customers, Pritchard EV, a nationwide distributor and subsidiary of Pritchard Companies, and the Southern California-based dealer Tom's Truck Center. The company also announced that Industrial Power & Truck Equipment and New England Truck Solutions are new dealers for the US market. REE has entered into an agreement with Mitsubishi (MUFG) HC Capital America to provide a customized finance solution for dealers within the REE network. This agreement is designed to streamline the process of obtaining financing for dealers looking to purchase REE Powered vehicles. Furthermore, Mitsubishi HC Capital America will leverage its existing relationships to help expand REE's North American dealer network. "We've set 2023 as a year to strongly grow our market share in the US," said Daniel Barel, Co-Founder and CEO of REE Automotive. "As part of our go-to-market strategy and getting REE-powered vehicles into the hands of fleet owners, we recognize the importance of a dealer-fleet relationship especially around maintenance and support and are on our way to building out a nationwide network of authorized dealers with partners such as Pritchard EV, Tom's Truck Center, Industrial Power & Truck Equipment and New England Truck Solutions which are staunchly committed to electrification and to providing their customers with the ultimate EV experience."

07:24 EST XPO Logistics announces Frye joined its board of directors - XPO (XPO) announced that J. Wes Frye has joined the company's board of directors, effective immediately. His appointment expands the composition of the board to nine members, of which seven are independent directors. Frye served as a 30-year executive with Old Dominion Freight Line (ODFL), including 18 years as chief financial officer, until his retirement in 2015.

07:22 EST First Wave BioPharma announces first patient dosed in Phase 2 SPAN trial - First Wave BioPharma announced that the first patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. Topline results from the study are anticipated by mid-2023. "Dosing of the first patient in the Phase 2 SPAN clinical trial is a significant milestone for First Wave BioPharma and a key inflection point towards our goal of developing adrulipase to one day replace porcine-derived pancreatic enzyme replacement therapy as the standard of care for EPI associated with CF and chronic pancreatitis," said James Sapirstein, President and CEO of First Wave BioPharma. "With dosing initiated, we now look forward to a topline data readout from the Phase 2 SPAN trial by mid-2023, which we hope will confirm the favorable results produced in the in vitro studies of the enteric microgranule delivery formulation for adrulipase."

07:19 EST Xos introduces 2023 Battery-Electric Stepvan - Xos introduced its 2023 Battery-Electric Stepvan. The next-generation Stepvan introduces several engineering changes that will significantly reduce direct material costs and strengthen the Company's gross margins, while offering enhanced technology capabilities and savings for customers. Built on the medium- and heavy-duty X-Platform chassis that is on the road today operating in fleets in parcel delivery, uniform rental, and cash-in-transit industries, the 2023 Xos Stepvan features an enhanced telematics module and over-the-air software capabilities. Updates received via over-the-air offer additional features and improvements that will enhance the vehicle's performance, while the telematics module enables advanced remote diagnostics for subscription customers of Xosphere(R), the Company's proprietary fleet management platform.

07:16 EST Surface Oncology announces anticipated near-term corporate milestones - In the first half of 2023, Surface expects to present updated clinical data from the ongoing Phase 2 trials investigating SRF388 in liver and lung cancer. Initial safety and efficacy data from the ongoing SRF114 Phase 1/2 clinical study are anticipated in 2024.

07:15 EST AstraZeneca announces ADAURA trial meets secondary endpoint - Results from the ADAURA Phase III trial showed AstraZeneca's Tagrisso demonstrated a statistically significant and clinically meaningful improvement in overall survival, or OS, a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent. In May 2020, AstraZeneca announced Tagrisso demonstrated a statistically significant and clinically meaningful improvement in disease-free survival, or DFS, in this setting. In September 2022, updated results demonstrated a median DFS of nearly five and a half years. Per the ADAURA trial protocol, patients on placebo that recurred with metastatic disease had the opportunity to receive open-label Tagrisso. The safety and tolerability of Tagrisso in the ADAURA trial were consistent with its established profile and no new safety concerns were reported.

07:13 EST BioXcel Therapeutics announces anticipated milestones - Anticipated Milestones: Clinical Trial Readouts: Top-line data from pivotal TRANQUILITY II trial in Q2 2023; Top-line efficacy data from pivotal SERENITY III trial in Q2 2023; Top-line results from Phase 1b MAD trial for MDD program in Q2 2023. Clinical Trial Initiations; Initiate SERENITY III Part 2 in Q2 2023;Initiate Phase 2b potential pivotal study of BXCL701 in SCNC in 2H 2023.

07:11 EST BioXcel Therapeutics evaluating strategic options for OnkosXcel - Actively evaluating strategic options for OnkosXcel Therapeutics, including potential partnering or third-party investments.

07:08 EST Fulcrum Therapeutics CMO Santiago Arroyo departs, Iain Fraser named interim - Iain Fraser, MBChB, D.Phil was appointed Interim CMO, effective March 9, 2023. He most recently served as Vice President and Clinical Fellow at AlloVir, an Elevate Bio Company.

07:05 EST Galecto announces anticipated 2023 milestones - Anticipated 2023 Milestones: Top-line results from Phase 2b GALACTIC-1 trial, mid-2023; Interim safety data from Phase 2a GALLANT-1 trial, Q2 2023; Top-line results from Phase 2a MYLOX-1 trial, Q4 2023; Initiation of Phase 2 investigator-initiated GB1211 oncology trial, 2H 2023.

07:04 EST Caesarstone CEO Yuval Dagim to step down, Yosef Shiran to succeed - Caesarstone announced that Yosef Shiran has been appointed as its CEO. Shiran, who previously served as Caesarstone's CEO from 2009 to 2016, will reassume the role on March 16. Following Shiran's appointment, Yuval Dagim, the current CEO, will step down and assist in ensuring business continuity and a transition.

07:03 EST Foghorn Therapeutics expects cash to fund operations into 2H25 - As of December 31, 2022, the Company had $345.8 million in cash, cash equivalents and marketable securities, providing cash runway into the second half of 2025.

06:57 EST Evofem CFO Jay File to depart, Albert Altro named as interim CFO - Evofem Biosciences announced the appointment of Albert Altro as interim CFO of the company. He replaces Jay File, who is leaving the company to explore other opportunities.

06:54 EST AstraZeneca says Tagrisso showed 'strong' overall survival benefit in trial - AstraZeneca announced "positive" high-level results from the ADAURA Phase III trial showed AstraZeneca's Tagrisso demonstrated a statistically significant and clinically meaningful improvement in overall survival, or OS, a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, after complete tumor resection with curative intent. In May 2020, AstraZeneca announced Tagrisso demonstrated a statistically significant and clinically meaningful improvement in disease-free survival, or DFS, in this setting. In September 2022, updated results demonstrated a median DFS of nearly five and a half years. Per the ADAURA trial protocol, patients on placebo that recurred with metastatic disease had the opportunity to receive open-label Tagrisso, the company said.

06:50 EST Herc Holdings CFO Mark Irion to resign, Mark Humphrey to succeed - Herc Holdings (HRI) announced that, effective March 10, Senior Vice President and CFO Mark Irion will resign his position for another opportunity. He will remain with Herc Holdings through March 31 to ensure a smooth internal succession process. Irion joined Herc Holdings in June 2018. The company is pleased to announce that, effective March 10, Mark Humphrey, previously the company's Vice President and Chief Accounting Officer, will be promoted to Senior Vice President and CFO. Humphrey joined Herc Holdings in April 2017 from Alico (ALCO), a publicly traded agribusiness and resource-management company, where he served as CFO and as Chief Accounting Officer. His nearly 30-year career also includes roles as CFO for Compass Management Group, a property-management company, and nearly 10 years in public accounting with PricewaterhouseCoopers LLP. Also, effective March 10, Mark Schumacher, the company's Vice President, Controller, will assume the additional role as Chief Accounting Officer. Schumacher joined Herc Holdings in February 2017 and has nearly 25 years of audit, accounting and financial reporting experience, including Global Controller for GE's Automation and Controls division, Vice President, Corporate Controller, for SunEdison, Inc., and 14 years in public accounting with KPMG LLP.

06:42 EST Norfolk Southern CEO delivers testimony before U.S. Senate Committee - Norfolk Southern president and CEO Alan Shaw will deliver testimony Thursday before the U.S. Senate Committee on Environment and Public Works. Below is his testimony as provided to the committee. Shaw said, "Chairman Carper, Ranking Member Capito, and distinguished members of the Committee, thank you for the opportunity to appear today to discuss the train derailment in East Palestine, Ohio. My name is Alan Shaw, and I have been the President and CEO of Norfolk Southern since May 2022. I look forward today to sharing our progress cleaning the derailment site, assisting families whose lives were disrupted, investing in the community, and making Norfolk Southern and the railroad industry safer. I am deeply sorry for the impact this derailment has had on the people of East Palestine and surrounding communities, and I am determined to make it right. We will clean the site safely, thoroughly, and with urgency. We are making progress every day. Working now under the U.S. Environmental Protection Agency's recent Unilateral Administrative Order, we have submitted a long-term removal plan that will guide our comprehensive testing program for the community's water, air, and soil. That testing is guided by science, and we will continue to share the results transparently. The Ohio and U.S. Environmental Protection Agencies, as well as other local agencies, are continually monitoring the air and water quality in East Palestine and report that both the air and water are safe. Financial assistance cannot change what happened, but it is an important part of doing the right thing. To date, we have committed to reimbursements and investments of more than $20 million in total, including by helping more than 4,200 families through our Family Assistance Center located in East Palestine. Supporting first responders has been a particular area of focus, and our contributions include more than $3 million to assist the East Palestine Fire Department. I would like to express again my profound admiration for the first responders from Ohio, Pennsylvania, and West Virginia who responded to the derailment. I want to be clear: this financial assistance is just a down payment. I've met with community leaders, business owners, school officials, clergy, and others to begin to identify ways we can invest in the future prosperity of East Palestine and support the long-term needs of its people. We will continue to invest in East Palestine for as long as it takes to help the community recover and thrive. We are also committed to learning from this accident and working with public officials and the industry to make railroads even safer. In the meantime, we have already launched a series of immediate steps to enhance safety, based on the facts in the National Transportation Safety Board's preliminary report. We look forward to cooperating with the NTSB as it continues its investigation into the root cause of the accident as well as its wider investigation... To date, monitoring of East Palestine's public drinking water and private water wells by multiple state and local authorities and Norfolk Southern shows that the water is safe to drink and there are no harmful levels of substances related to the derailment. Beginning immediately after the derailment and now at the direction of the U.S. EPA, we have implemented a comprehensive testing program to monitor the quality of the community's air. The U.S. EPA has monitored air near schools and residential areas, in several government buildings, upwind of the derailment site, and downwind of the derailment area. Norfolk Southern's outdoor air monitoring program has collected millions of data points from around the derailment site and throughout the community. The results of these tests continue to demonstrate that the air is safe to breathe. In addition, in consultation with the U.S. EPA, we have been performing indoor air quality screening for residents. To date, nearly 600 homes have been screened; none of the results indicate a health risk from incident-related substances. We continue to listen to the experts and cooperate with state, federal, and local government agencies. We are committed to this monitoring for as long as necessary. We have also created a website, NSMakingItRight.com, to provide the latest information to residents of East Palestine and the surrounding communities... We have committed another $7.5 million in financial assistance to reimburse Pennsylvania emergency responders and health and environmental agencies for costs related to the derailment. And I personally have committed almost $450,000 to fund scholarships for seniors at East Palestine High School... Finally, Chairman Carper, Senator Capito and members of the Committee, I want to state again how deeply sorry we are for the impact of this derailment on East Palestine, surrounding communities and all of the people who have been affected. We are making progress in the recovery and know our work is not yet done. On behalf of the more than 19,700 hard-working employees of Norfolk Southern, I pledge that we won't be finished until we make it right. Thank you for the opportunity to testify before you today, and I look forward to your questions."

06:38 EST Townsquare Media initiates quarterly cash dividend of 18.75c per share - The company also announced that its board of directors approved the initiation of a quarterly cash dividend of 18.75c per share. The dividend will be payable on May 1 to shareholders of record as of the close of business on March 27.

06:32 EST JD.com initiates quarterly dividend of 62c per ADS - The company announced that its board of directors approved a cash dividend of 31c per ordinary share, or 62c per ADS, to holders of ordinary shares and holders of ADSs, respectively, as of the close of business on April 6, Beijing/Hong Kong Time and New York Time, respectively, payable in U.S. dollars. The aggregate amount of the dividend will be approximately $1B. The payment date is expected to be on or around April 27 and on or around May 4 for holders of ordinary shares and holders of ADSs, respectively. In addition, the company plans to adopt an annual dividend policy, under which the company may choose to declare and distribute a cash dividend each year, starting from 2023, at an amount determined in relation to the company's financial performance in the previous fiscal year, among other factors. The determination to make dividend distributions in any particular year will be made at the discretion of the Board based upon factors such as the company's results of operations, cash flow, financial condition, capital requirements and other considerations that the board deems relevant.

06:19 EST GE sees mid to high teens organic revenue growth for GE Aerospace in FY23 - For GE Aerospace, sees $5.3B-$5.7B operating profit and FCF up year over year. For GE Vernova, sees LSD to MSD organic revenue growth, with ($0.6B)-($0.2B) operating profit and FCF flat to slightly improved. Sees more than doubling adjusted EPS in 2023. GE's 2023 forecast includes about $1B of remaining separation costs.

06:10 EST BJ's Wholesale CEO says 'our membership base is stronger than ever' - "2022 was a record year, having surpassed $1 billion in Adjusted EBITDA for the first time in the company's history," said Bob Eddy, President and CEO, BJ's Wholesale Club. "Our membership base is stronger than ever with our tenured renewal rate reaching an all-time high of 90%. Our continued focus on value has driven traffic and market share gains all year. Our digital business is growing and we're successfully expanding our footprint. The investments we continue to make in our company position us well for long-term growth and sustainable value creation."

06:07 EST Dime Community raises quarterly dividend to 25c from 24c per share - The dividend is payable on April 24 to common stockholders of record as of April 17.

05:56 EST Meta's Oversight Board to review handling of election content in Brazil - Meta's Oversight Board has agreed to review a case related to Meta's handling of election content in Brazil. In a statement, the board said they planned to scrutinize the social network's policies surrounding election content in "high-risk" areas. The case stems from a user who posted a video in early January calling for people to "besiege" Brazil's congress following the election of President Lula da Silva. The Oversight Board said: "The Board selected this case to explore Meta's policies and practices in moderating content that targets people based on a protected characteristic, such as sex and gender. This case falls within the Board's "Gender" and "Hate speech against marginalized groups" strategic priorities." Reference Link

05:22 EST Airspan Networks sells Mimosa Networks to Radisys for $60M - Airspan Networks and Radisys, a wholly owned subsidiary of Jio Platforms, announced the sale of Mimosa Networks, to Radisys for $60M on a debt free, cash free basis. Airspan acquired Mimosa in 2018 to target cost effective fixed wireless access network connections. Mimosa has a portfolio of point-to-point and point-to-multi-point products based on WiFi 5 and the newer WiFi 6E technologies as well as related accessories, such as twist on antennas, PoE Injectors, etc. These solutions have use cases in the backhaul requirements for 5G and FTTX/ FWA rollouts. Jio has been a major customer of Mimosa. Mimosa's product development, manufacturing, and sales teams of 56 employees will continue with Mimosa following the acquisition by Radisys. Airspan maintains a reseller channel for specific joint 4G/5G and FWA projects and will continue marketing Mimosa products to some of its customers following the acquisition. Jio is a shareholder of Airspan and maintains a seat on its Board of Directors. The transaction is subject to certain regulatory and other customary closing conditions, including the US CFIUS review and approval by Airspan's senior lender and is expected to complete in the third quarter of 2023.

05:18 EST Qiagen enters strategic partnership with Servier - Qiagen announced it has entered into a strategic partnership with Servier, a pharmaceutical group, to develop a companion diagnostic test for Tibsovo, an isocitrate dehydrogenase-1, or IDH1, inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia, or AML. Under the master collaboration agreement, Qiagen will develop and validate a real-time in vitro PCR test that can be used to detect IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates. The companion diagnostic will run on the QIAGEN Rotor-Gene Q MDx device, which is widely used by labs worldwide. QIAGEN's experienced regulatory teams will support clinical validation of the companion diagnostic and its approval in the U.S., the European Union and Japan.

05:10 EST Stellantis allocates BEV-centric STLA Large platform to Cassino Assembly Plant - Stellantis Cassino Assembly Plant in Italy, producer of vehicles for Alfa Romeo and Maserati, will add production of vehicles, to be shared at a later date, based on the BEV-centric STLA Large platform. The announcement was made by Stellantis CEO Carlos Tavares as he visited the assembly plant, which builds the Alfa Romeo Giulia and Stelvio as well as Maserati Grecale vehicles. Cassino is the second Stellantis plant publicly named to produce vehicles based on the STLA Large platform, joining the Windsor Assembly Plant in Canada. Opened in 1972, the Cassino Assembly Plant in Piedimonte San Germano, south central Italy is a highly automated plant using more than 1,200 robots and includes stamping, plating, painting and plastic parts operations. The plant puts a high emphasis on energy and resource conservation. It has cut its use of water by half since 2017 and captures solar energy via photovoltaic cells positioned in its parking lots. STLA Large is one of four BEV-centric, highly flexible vehicle architectures that underpins the Stellantis electrification plan. The STLA Large platform, the base for several upcoming vehicles from Stellantis brands, is designed to deliver up to 800 km/500 miles of electric range with Stellantis-designed electric drive modules (EDMs) and modular battery packs. Designers and engineers have the flexibility to adjust the platform's length and width and powertrain configuration to tailor it to specific product designs. Stellantis is investing more than EUR 30B through 2025 in electrification and software to deliver BEVs that meet customer demands, including class-leading fast charge capability.